title: Effect of excipients on the particle size of precipitated pioglitazone in the gastrointestinal tract: impact on bioequivalence.
abstract: This study sought to understand the reasons for the bioinequivalence of a newly developed generic product of pioglitazone hydrochloride and to improve its formulation so that it is equivalent to that of the reference listed drug (RLD). In this clinical study, despite a similar in vitro dissolution profile, the new oral product exhibited a lower plasma concentration of pioglitazone compared to the RLD. The strong pH-dependency of pioglitazone solubility as a weak base indicates that pioglitazone would precipitate in the small intestine after being dissolved in the stomach. Thus, in vitro experiments were performed to investigate the effect of excipients on the particle size distribution of precipitated pioglitazone. Then, the impact of particle size on in vivo absorption was discussed. The precipitated pioglitazone from the RLD showed a peak for small particles (less than 1 μm), which was not observed in the precipitate from the new product. As an excipient, hydroxypropyl cellulose (HPC) influenced the particle size of precipitated pioglitazone, and the amount of HPC in the formulation was increased to the same level as that in the RLD. The precipitate from this improved product showed approximately the same particle size distribution as that of the RLD and successfully demonstrated bioequivalence in the clinical study. In conclusion, for drugs with low solubility, this type of analysis of the particle size distribution of precipitated drugs, in addition to the dissolution test, may help to obtain a better in vitro-in vivo correlation for oral absorption and to develop a bioequivalent product.
authors: Sawai Pharmaceutical Co., Ltd., 5-2-30 Miyahara, Yodogawa-ku, Osaka, Osaka, 532-0003, Japan, m.sugita@sawai.co.jp.
authors: Masaru
authors: M
authors: Sugita
authors: Makoto
authors: M
authors: Kataoka
authors: Masahisa
authors: M
authors: Sugihara
authors: Susumu
authors: S
authors: Takeuchi
authors: Shinji
authors: S
authors: Yamashita
mesh_terms: D000284:Administration, Oral; D002482:Cellulose / Q000031:analogs & derivatives* / Q000737:chemistry; D011232:Chemical Precipitation; D002626:Chemistry, Pharmaceutical; D018592:Cross-Over Studies; D016568:Drugs, Generic / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D005079:Excipients / Q000737:chemistry*; D064368:Healthy Volunteers; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000097:blood / Q000737:chemistry / Q000493:pharmacokinetics*; D007408:Intestinal Absorption; D008297:Male; D010316:Particle Size; D000077205:Pioglitazone; D012995:Solubility; D013810:Therapeutic Equivalency; D045162:Thiazolidinediones / Q000008:administration & dosage / Q000097:blood / Q000737:chemistry / Q000493:pharmacokinetics*
chemical_list: D016568:Drugs, Generic; D005079:Excipients; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D002482:Cellulose; C008079:hydroxypropylcellulose; D000077205:Pioglitazone